Product Description
Mechanisms of Action: GnRH Agonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Topical,Nasal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Ireland | Norway | Poland
Approved Indications: None
Known Adverse Events: None
Company: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Dwarfism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2011-00975 | P2 |
Active, not recruiting |
Breast Cancer |
2024-09-15 |
|
83-CH-0199 | P2 |
Completed |
Dwarfism |
None |